Products
Preparation registered in Ukraine
ÓÄÊ 616.8-009.188.4-085.273+615.273
Special role of cilostazol on the treatment of patients with manifestation of claudication intermittent acording to the recommendations evidence-based medicine
I.M.Gudz
Conducted the analysis of data from evidence-based medicine in relation to conservative treatment for patients with peripheral occlusive disease in the stage of claudication "intermittent" (CI). Presented the data of numerous studies that substantiate the pathogenetic advisability of cilostazol (CS) for the treatment of these patients. Results of a multicenter randomized placebo-controlled trials indicate the clinical and economic benefits CS of the construction pentoxifyllin and other vasoactive drugs in the treatment plan for patients with manifestations CI. In addition there is also extensive evidence base on the safety of long-term appointment CS.
Keywords: cilostazol, claudication "intermittent", treatment, evidence-based medicine